Check-Cap Ltd. Ordinary Share (MBAI)
StalwartFairStock Score: 36/100 — MIXED
Key Financials
| Current Price | $1.77 |
| Market Cap | $11M |
| P/E Ratio | 2.68 |
| ROE | 416.71% |
| Dividend Yield | —% |
| Sector | Healthcare |
Strengths
- Generates $858,875 in annual free cash flow (7.8% yield on market cap)
- High return on equity of 416.7% demonstrating efficient capital deployment
- Conservative balance sheet with debt-to-equity of just 0.00, providing financial flexibility
Concerns
- Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
- Weak Piotroski F-Score of 0/9 suggests deteriorating financial quality across multiple dimensions
- Altman Z-Score of -632.7 places it in the financial distress zone—elevated bankruptcy risk
AI Analysis
Check-Cap Ltd. Ordinary Share is a micro-cap healthcare company valued at $11 million. From a quality standpoint, Check-Cap shows weak Piotroski F-Score of 0/9 signaling deteriorating fundamentals and distressed Altman Z-Score of -632.7 warrants caution. On valuation, the stock is deeply undervalued on a P/E basis at 2.2x, with solid 7.8% FCF yield. Our composite FairStock Score of 36/100 reflects below-average fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.
Bull Case
The market underappreciates Check-Cap's consistent 417% ROE at just 2x earnings—a re-rating toward sector peers could unlock 30-50% upside. With $858,875 in annual free cash flow (7.8% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.
Bear Case
Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer